CSL Ltd (ASX: CSL) shares are climbing higher into the green in Thursday lunchtime trade.

At the time of writing, the shares are up around 0.5% and changing hands for $122.29 a piece.

Today’s uptick means the ASX biotech shares have now climbed around 15% over the past month and have rebounded 33% since a 15-year low in early June.

But there is still a long way for CSL shares to go before they’ve recouped the huge amount of losses shed over the past 18 months.

The shares are still down around 29% for the year-to-date and are 51% lower than trading prices 12 months ago.

The latest rebound is certainly a step in the right direction. But the question now is, can CSL shares keep climbing higher?

Here’s what the experts expect from the biotech stock over the next 12 months.

Buy, sell or hold: Here’s what brokers tip for CSL shares

It looks like market sentiment for CSL shares has shifted recently. Previously, brokers were incredibly bullish about the ASX healthcare shares and were confident of a strong upside ahead.

But now it looks like there’s a little more caution in the market.

Market Index data shows that the majority of brokers now have a hold rating on CSL shares. The $131.48 target price implies a potential 8% upside at the time of writing.

TradingView data also shows some ratings downgrades. Out of 18 analysts, 10 now have a hold stance on the biotech company’s shares, and another eight have a hold or strong hold rating.

The average target price is a little higher at $140.15, which implies a potential 15% upside at the time of writing. But some are still bullish that CSL shares could climb 64% to $199.68 over the next 12 months.

Morgans is one of the more optimistic brokers. It has a buy rating with a price target of $147.59, implying a robust upside ahead. The broker notes that CSL’s long-term story remains intact. However, it thinks that a sustained recovery in sentiment may take several quarters to fully materialise while investors wait for clear improvement in the company’s financials.

Elsewhere, the team at Macquarie is more cautious. The broker has a lower price target of $114 and a neutral stance. It cites uncertainty across CSL’s core plasma and albumin businesses, as well as ongoing competitive pressures.

My view on CSL shares

The latest rebound shows that investors are now looking forward to the company’s FY26 results announcement and any sign that management has been able to improve operations. 

I think there is a lot of potential for the company over the next few years. After all, CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products. 

Global demand for plasma therapies is strong and growing, too. There is recurring demand and limited competition, which makes CSL well-placed to carve out a significant portion of the market.

I think that once CSL is able to turn around its financials, investor confidence will follow.

The post Here’s what brokers tip for CSL shares over the next 12 months appeared first on The Motley Fool Australia.

More reading

• How have CSL shares performed over 10 years?
• The Macquarie share price just hit a new record high
• How I’d invest $10,000 in ASX shares for the next decade
• What did the market look like 10 years ago? Here’s what’s changed for the ASX 200
• Would Warren Buffett buy CSL shares?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The analyst team at Macquarie has recently issued new research notes on various companies in the resources sector.

I’ve picked out two ASX shares which might be of interest, respectively in the gas and mineral sands sectors.

Let’s have a look at who they like.

Amplitude Energy Ltd (ASX: AEL)

Macquarie notes in its recent report on Amplitude that the company is on track for a final investment decision for its East Coast Gas Project this quarter and first production in FY28.

Amplitude shored up the project in May, buying half of the Artisan gas field in the offshore Otway Basin from Beach Energy Ltd (ASX: BPT) for $58.3 million.

Amplitude Managing Director Jane Norman said regarding the deal:

Producing Artisan through Amplitude Energy’s existing infrastructure allows faster and lower-cost development of this gas for the east coast domestic market. Artisan development costs will significantly benefit from leveraging the existing East Coast Supply Project (ECSP) program and our readily-available infrastructure. This is a win-win for Amplitude, O.G. Energy and Beach with respect to optimising our respective Otway Basin positions. We expect to rapidly move to FID on the development phase of the ECSP over the next few months while the drilling of the Juliet and Annie wells is conducted, with Juliet now brought forward and drilling expected to commence by late July or early August.

Macquarie said there was downside pressure on gas prices from the Federal Government’s gas reservation scheme, but also noted that 80% of Amplitude’s 2026 gas volumes were under contract.

They added:

Latest gas market interventions drive a structural oversupply in domestic gas markets, but we believe incentives may ultimately be required to encourage investment in backfill supply projects (eg. carve outs, subsidies, creation of domestic trading credit market).

Macquarie has a price target of $2.15 on Amplitude shares compared to $1.49 currently.

Iluka Resources Ltd (ASX: ILU)

Macquarie said zircon pricing improved in the first quarter of 2026, with improved Chinese sentiment and tight premium zircon supply supporting the market.

In contrast, titanium dioxide markets remained weak, while rutile prices were also depressed through the second quarter, Macquarie said.

Despite that weakness, Macquarie has a bullish share price target on the stock of $8 compared to $6.30 currently.

The broker added:

While we see early signs of recovery in zircon markets, titanium dioxide feedstock markets remain weak and continue to present an earnings headwind for ILU. Construction of Eneabba Phase 3 remains underway, with completion targeted for 2HCY27, requiring investors to maintain a longer-term investment horizon.

The post A miner and an energy company to buy according to Macquarie appeared first on The Motley Fool Australia.

More reading

• Why this ASX energy stock could be set to rise 80%: Expert
• 2 ASX growth shares with strong potential to buy
• Amplitude Energy shares could be set to soar 90%: Expert
• Are these oversold ASX shares too good to pass up?
• This ASX gas company could more than double in value: Broker

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ResMed Inc (ASX: RMD) shares have fallen by more than 25% over the past year, which begs the question: Is now the time to buy in?

ResMed shares looking cheap according to analysts

The analyst team at Morgans has run the ruler over the company, and has a buy recommendation on the stock and a bullish share price target, which we’ll get to shortly.

The reason the Morgans team had another look at ResMed was because of the company’s recent move to sell its MatrixCare division for US$490 million, with that sale expected to be completed in the first quarter of FY27.

ResMed said the sale would allow it to focus more strongly on its core business.

As it said:

This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem.

MatrixCare is a software business focused on “nursing, senior living and long-term care, life planning communities, and home health and hospice care”.

The Morgans team said they believed the transaction made sense as it would simplify the ResMed business.

They added:

Importantly, net proceeds will largely be returned to shareholders via an accelerated share repurchase (ASR), which should substantially offset earnings dilution from both the MatrixCare disposal and the recently completed Noctrix acquisition, while FY26 guidance has been reaffirmed.

Morgans said MatrixCare, which ResMed acquired for US$750 million in 2018, had been a disappointing acquisition for the company.

Morgans said:

During this time, earnings increased from ~US$30m to ~US$55m, implying modest long-term earnings growth. While this reflects poorly on the original acquisition, we believe exiting today is preferable to continuing to allocate capital toward a mature business with limited strategic alignment.

ResMed target price has been reduced

Overall, Morgans remains positive on ResMed’s outlook; however, they slightly reduced their price target to $41.72.

As they said:

We view RMD’s fundamentals as sound, with consistent execution, strong cash generation and structural growth tailwinds from expanding diagnosis and resupply. We have a BUY rating with a sum of the parts/discounted cash flow target price of $40.97.

ResMed shares were changing hands for $28.25 on Thursday.

The company is valued at $40.06 billion and pays an unfranked 1.23% dividend yield.

ResMed will report its fourth quarter earnings on 6 August.

The post How much could ResMed shares rise according to Morgans? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares
• 3 ways to get from $100,000 to $500,000 in retirement savings
• 5 things to watch on the ASX 200 on Thursday
• How I’d invest $10,000 in ASX shares for the next decade
• 10 fantastic ASX shares to buy for FY27

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.